Arcellx announces presentation of new clinical data from its cart-ddbcma phase 1 trial in patients with relapsed or refractory multiple myeloma at the 64th ash annual meeting and exposition

-- ash abstract contains previously presented data from june 2022 -- -- new clinical data from a recent data cut will be presented at ash -- -- company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on sunday, december 11, 2022, at 11:00 a.m. ct -- redwood city, calif.
ACLX Ratings Summary
ACLX Quant Ranking